NeXT Liquid Biopsy™
It’s Time to Think About More.
High-Performance Whole Exome Sequencing from Plasma.
Highlights
- Comprehensively profile the tumor, exome-wide
Combined with ImmunoID NeXT™, assess tumor heterogeneity, monitor response to therapy, and interrogate mechanisms of resistance - Profile with ImmunoID NeXT, Monitor with NeXT Liquid Biopsy
Leverage somatic variant results from the solid tumor, and monitor them for longitudinal analysis, while also detecting de novo mutations as they occur - Discover more: Go beyond typical panel content
Exome-wide footprint ensures inclusion of important areas of tumor biology not typically covered in targeted panel approaches to fuel clinical and translational research - Unprecedented performance at exome scale
Innovative library preparation, high depth of sequencing, and advanced error suppression techniques deliver results you can trust
